title: Gallium-68 DOTANOC imaging in paraganglioma/pheochromocytoma: presentation of sample cases and review of the literature.
abstract: Gallium-68 DOTANOC is a high affinity somatostatin receptor ligand, first introduced in 2005 for imaging neuroendocrine tumors. Due to its technically simple production, broad availability, favourable biodistribution and advantageous dosimetry, although not approved yet in all European countries, gallium-68 DOTANOC has rapidly gained acceptance in the diagnostic and therapeutic work-flow of different types of neuroendocrine tumors. Principal indications in clinical practice in countries where it is officially approved include diagnosis and staging, restaging after treatment, identification of sites of unknown primary and selection of patients with neuroendocrine tumors eligible for therapy with somatostatin analogues.
authors.affiliation: Nuclear Medicine Department, Humanitas Clinical and Research Center Rozzano, Italy. egesta.lopci@gmail.com
authors.forename: E
authors.initials: E
authors.lastname: Lopci
authors.forename: L
authors.initials: L
authors.lastname: Zanoni
authors.forename: S
authors.initials: S
authors.lastname: Fanti
authors.forename: V
authors.initials: V
authors.lastname: Ambrosini
authors.forename: M R
authors.initials: MR
authors.lastname: Castellani
authors.forename: C
authors.initials: C
authors.lastname: Aktolun
authors.forename: A
authors.initials: A
authors.lastname: Chiti
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D009942:Organometallic Compounds; D010235:Paraganglioma / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals
chemical_list: C504894:68Ga-DOTANOC; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals